New Motion Preserving Wrist Implant hits 1 year Milestone

FRANKLIN, Mass., Sept. 12, 2016 /PRNewswire/ — In May of 2015 the new motion preserving WristMotion™ hemiarthroplasty implant from Arthrosurface, Inc. ( was launched. The following month, the first patients were treated by the three co-developing surgeons, Dr. Randall Culp, Dr. Joseph Sherrill and Dr. Insok Yi. The WristMotion™ implant system is designed to intraoperatively map the curvature of the patients’ wrist joint and resurface the arthritic bone with a congruent and robust articular surface implant. To date more than 100 procedures have been performed across the US with new surgeons treating more patients every month. The product was launched at the ASSH Hand Meeting in September of 2015 to an overwhelmingly positive response.

There are a variety of conditions that lead to pain and arthritis in the hand joint, many of which are caused by previous trauma or chronic overuse. Historically, when patients developed arthritis in their wrist, several procedures were performed: a PRC (Proximal Row Carpectomy), a 4 corner fusion (4CF) or a joint replacement with implants. The implants either replaced one side (hemi) or both sides of the joint (Total). In the PRC procedure, the arthritic bones in the middle of the hand were removed and a new articulation formed between the remaining bones. In the 4 corner fusion procedure, the arthritic bones were left intact but immobilized so they no longer move against each other. The idea was that once the bones fused together, the pain would go away. Total replacements were performed more commonly than hemi’s and they involved significant bone resection. The WristMotion™ system consists of an anatomic implant to resurface the arthritic capitate bone. The implant creates a new articulating surface and is designed to preserve more bone than other implants, thereby providing patients with an alternative to other treatments.

Dr. Randy Culp said, “The bones in the hand are very uniquely shaped and contribute to the overall mobility of the hand. Whether we fuse or remove the bones for a PRC, we are making a compromise. Now that we can use an implant to reshape the bones to match each other, we have another way to preserve motion.” Follow-up on early patients has shown that the implants are stable, patients are able to return to their previous activities with pain-free motion and many have returned to sports such as golf.

Previously, surgeons promoted fusions or PRC’s over joint replacements. That thinking is starting to change. As Dr. Joseph Sherrill commented, “In spite of initial successful outcomes following PRC or four corner fusions, there is a significant failure rate over time due to progressive radio carpal arthritis. The WristMotion™ implant is an excellent treatment option for these patients who may be considering fusion but would prefer to maintain wrist motion.”

The WristMotion™ system is based on the same time tested principles of other Arthrosurface joint restoration systems. Match the implant to the patient and restore joint congruency using instrumentation that is reproducible and intuitive. “When I saw how well the knee and shoulder patients of my partners functioned when they used Arthrosurface, I thought that we needed something like that for the wrist. As hand surgeons we operate in a small space so instruments and implants need to be streamlined and small. The WristMotion™ system is extremely intuitive and reproducible which makes the procedure reliable and quick,” said Dr. In Sok Yi.

Steven Ek, CEO, Arthrosurface commented, “We are very excited about expanding our joint preserving technology into the hand and wrist. By adding new products to our extremity portfolio, surgeons have more options to treat disabling arthritis with unique and motion preserving solutions. For Arthrosurface, the extremity product line is a key to driver for our growth.”

About Arthrosurface

Arthrosurface, Inc. is a leader in the design and distribution of orthopedic devices for joint preservation, restoration and resurfacing. The HemiCAP® system is a unique, less invasive technology that can be used to treat a wide variety of joint conditions caused by trauma, injury and disease. Founded in 2002, Arthrosurface markets and distributes its products in the US and around the world.

Logo –

SOURCE Arthrosurface, Inc.

Related Links

New foot and ankle surgeon joins Coastal Orthopedics

September 7, 2016

BRADENTON, Fla. — Dr. Andrés E. O’Daly, an orthopedic surgeon specializing in foot and ankle treatments, has just joined the comprehensive and full-service practice Coastal Orthopedics Sports Medicine & Pain Management (

For the past year, Dr. O’Daly has been completing a foot and ankle surgery fellowship through the Department of Orthopaedic Surgery at the University of Alabama at Birmingham. He earned his Doctor of Medicine degree and completed his first orthopedic residency at the Central University of Venezuela.

“Since I was in Venezuela, I was interested in the mechanics of the foot,” said Dr. O’Daly. “It’s a growing, constantly evolving specialty with lots of innovation.”

Dr. O’Daly practiced as an orthopedic surgeon in Centro Medico de Caracas, one of the most prestigious clinics in Venezuela, focusing on sports medicine and joint reconstruction.

While receiving his medical training, Dr. O’Daly volunteered for a two-year clinical program at the Venezuelan Red Cross and interned at the Dr. Raúl Perdomo Hurtado Naval Hospital in Venezuela.

Dr. O’Daly earned his second residency from Johns Hopkins University after completing a research fellowship on peripheral nerve regeneration.

At Coastal Orthopedics, Dr. O’Daly will treat patients suffering from a variety of foot and ankle issues, including athletic injuries, fractures, dislocations, sprains, heel pain, Achilles tendon problems, arthritis and more.

“At Coastal Orthopedics, the motive is always patient care first,” said Dr. O’Daly. “I love the people at Coastal Orthopedics and the office.”

In the coming months, Dr. O’Daly will continue to be involved in an ongoing research project in conjunction with Johns Hopkins and the University of Alabama at Birmingham focused on ankle joint fracture care.

When he was working toward his fellowship at Johns Hopkins, Dr. O’Daly was honored with the Frank L. Coulson Jr. award for Clinical Excellence for several accomplishments, including communication and interpersonal skills, professionalism and humanism, diagnostic acumen, skillful negotiation of the healthcare system, a scholarly approach to clinical practice and a passion for patient care.

Dr. O’Daly, who recently moved to Bradenton with his wife and two daughters, is a member of the American Association of Orthopaedic Surgery and the American Orthopaedic Foot and Ankle Society.

About Coastal Orthopedics Sports Medicine & Pain Management
Founded in 1973 and based in Bradenton, Fla., Coastal Orthopedics is home to 15 orthopedic surgeons and pain management physicians who maintain hospital affiliations with Blake Medical Center, Manatee Memorial Hospital and Lakewood Ranch Medical Center. In addition to three offices and two ambulatory surgery centers each serving Florida’s West Coast, Coastal Orthopedics’ board-certified and fellowship-trained physicians and surgeons provide patients with the very latest in pain and orthopedic treatment technology. The company strives to repair and heal injuries relating to the entire musculoskeletal system. For more than 40 years, our highly skilled staff of physicians and surgeons has treated patients in specialty care including sports medicine, joint replacement, pain management and rehabilitation. Patients can experience restoration of function both surgically and non-surgically through the use of physician-guided strengthening, therapy, medications, injections and stretching. For more information, please visit or call 941-792-1404.


In2Bones USA Completes Merger to Form i2b Global

September 07, 2016

MEMPHIS, Tenn. & LYON, France–(BUSINESS WIRE)–In2Bones USA, LLC and In2Bones, SAS announced today that the two companies have completed a series of transactions which will combine, pursuant to an all-stock share exchange, In2Bones, SAS with its largest distributor, In2Bones USA, LLC.

The merger officially closed on August 31, 2016.The merged companies have become wholly-owned subsidiaries of a holding company known as In2Bones Global, Inc. (dba: i2b Global), creating a global company specializing in the fast-growing upper and lower extremities orthopaedic markets.

i2b Global will continue to operate both of its subsidiaries in Memphis, Tenn., and Lyon, France. The corporate headquarters for i2b Global will be based in Memphis.

“The two companies have shared a distribution and development relationship for several months. This merger allows us to better coordinate product development and distribution around the world,” says Alan Taylor, orthopaedic industry veteran and President and Chief Executive Officer of i2b Global.

“We have known for some time that we needed to combine the companies in order to add scale and efficiencies for our rapidly expanding enterprise,” says Eric Fourcault, a founder of In2Bones and head of the company’s Lyon, France and non-U.S. interests. “We believe this action will further accelerate our growth in the global market.”

For more information about i2b Global extremity products in the U.S. and France, please visit or

About In2Bones USA, LLC

In2Bones USA, LLC is a designer, manufacturer and distributor of medical devices for the treatment of disorders and injuries of the upper (hand, wrist, elbow) and lower (foot and ankle) extremities. The company currently markets more than 12 products in the United States and has a product pipeline of 10 to 12 additional products slated for launch in the remainder of 2016 and 2017. For more information, visit

About In2Bones, SAS

Located in Lyon, France, In2Bones, SAS is a specialty orthopaedic company that develops and distributes upper and lower extremity products to enable surgeons to alleviate pain and restore motion for their patients. For more information, visit

Safe-Harbor Statement:

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this press release, other than statements of historical fact, are forward-looking statements. Forward-looking statements reflect management’s current view of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “will,” and other similar terms. The company wishes to caution readers that actual results might differ materially from those described in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties impacting the business, including increased competition, technical obsolescence, regulatory issues, general economic conditions and other risks.


Element-R Partners
Susan Duensing, CBC

Flower Orthopedics Debuts Next Generation Ready-for-Surgery™ Guide Wire Kits

HORSHAM, Pa., Sept. 7, 2016 /PRNewswire/ — Flower Orthopedics announces the full market launch of its next generation Ready-for-Surgery™ Guide Wire Kits for the Cannulated Screw FlowerCube™. The patent-pending Flower Guide Wire Kits reduce the number of surgical steps and are evidence of Flower’s continuing commitment to develop products that provide enhanced surgical efficiency in the OR.

“With the countersink and depth gauge combined in one instrument, Flower Orthopedics is providing solutions to surgeons that streamline the process of treating patients with internal fixation,” says Dr. Timothy Mineo of Portland, Oregon.

Flower is redefining the orthopedic extremity and trauma marketplace with its Ready-for-Surgery™ implants and instruments in the efficient FlowerCube™ system.  “In developing the next generation of Guide Wire Kits, the engineering team was able to improve a surgical process with elegance, maintaining our surgical efficiency objective and compounding our product differentiation within the marketplace,” adds Oliver Burckhardt, CEO & President of Flower Orthopedics.

Like all Flower products, the new Guide Wire Kits are single-use, sterile packaged and always Ready-for-Surgery™.

Flower Orthopedics: Surgical Efficiency Drives Healthcare Costs Savings

Whether it is addressing infection potential, eliminating set reprocessing expenses or preventing delays in the OR, the Flower Orthopedics Ready-for-Surgery™ portfolio is a proven method that surgeons and healthcare facilities use to reduce the overall cost of providing patient care.  Flower development team works tirelessly with leading surgeons to decrease the number of surgical steps of a given procedure and to design instruments that make surgeries faster and more reproducible. Combining the surgical efficiency with the inherent efficiencies of the Ready-for-Surgery™ model, Flower Orthopedics is reducing the cost of care for a wide range of extremity applications.

Please refer to for the Indications for Use

To view the original version on PR Newswire, visit:

Exactech Announces Investor Presentation at Baird Global Healthcare Conference

September 06, 2016

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products for extremities, knee, hip, spine and biologics, will present to investors at the Baird 2016 Global Healthcare Conference in New York on Wednesday, September 7, 2016. The company will also host one-on-one meetings with institutional investors.

The presentation by Exactech CEO David Petty and Executive Vice President of Finance & CFO Jody Phillips will begin at 4:20 p.m. ET, and will be available via live and archived webcast at The replay will be available for 90 days.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech, Inc. can be found at Copies of Exactech’s press releases, SEC filings, current price quotes and other valuable information for investors may be found at and

An investment profile on Exactech may be found at To receive future releases in e-mail alerts, sign up at

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.


Exactech, Inc.
Investor contacts:
Jody Phillips, 352-377-1140
Executive Vice President of Finance &
Chief Financial Officer
Hawk Associates
Julie Marshall or Frank Hawkins, 305-451-1888
Media contact:
Priscilla Bennett, 352-377-1140
Vice President, Corporate & Marketing Communication